AppliedVR

AppliedVR operates at the intersection of digital therapeutics, medical devices, and immersive computing. Its differentiation is the combination of an at-home VR delivery model with structured behavioral skills, mindfulness, and cognitive behavioral therapy for chronic pain. RelieVRx is described as an FDA-authorized prescription VR medical device, and the company has pursued Medicare coding, reimbursement, commercial health-plan contracts, and VA distribution. That reimbursement infrastructure creates a higher barrier to entry than a consumer wellness app, while the home-based format addresses clinician capacity and access constraints. SustainVR extends the platform into wellness and Veteran-focused support, giving AppliedVR a broader clinical and institutional use case than a single-condition product. AppliedVR’s category position is nevertheless distinct from general-purpose VR wellness providers because its primary proposition is regulated, evidence-backed therapeutic care. The principal market challenge is converting clinical evidence and payer coverage into repeatable utilization and durable reimbursement economics.

AppliedVR’s funding history shows a progression from a $6 million Seed round in 2016 to a $29 million Series A announced on Mar 23, 2021 and a $36 million Series B announced on Nov 11, 2021, bringing total funding to $71 million. The 2020 Series A entry has no disclosed amount, while the reported round totals reconcile to the company-wide figure. Product development then moved toward commercialization: RelieVRx was launched for workers’ compensation patients in May 2024, followed by Highmark coverage in September 2024. These events represent an inflection point from clinical development toward payer and channel expansion. Research announcements in July 2024 and May 2025 supported the evidence base, including findings across sociodemographic groups and hard-to-treat patients. With no later financing disclosed, the next trajectory signal is likely adoption and reimbursement growth rather than another clearly documented capital milestone.